Roche builds MRD testing arsenal in $595m Saga Diagnostics buyout [Yahoo! Finance]
Guardant Health, Inc. (GH)
Last guardant health, inc. earnings: 2/24 04:03 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
This merger will see Roche's precision medicine-focused subsidiary, Foundation Medicine, absorb Saga's Pathlight platform, which is designed to determine the best treatment option for a patient with cancer. It works by determining an individual's molecular response to therapy while assessing if their disease has recurred. Debuted by Saga in May 2025, Pathlight combines digital PCR with whole genome sequencing (WGS) to spot structural variants, which are large-scale genomic changes that can drive cancer growth, while allowing for “ultra-sensitive” detection of MRD in cancer. In a bid to develop a “decentralised MRD solution” that will enable patient access on a global scale, Foundation will combine Pathlight with Roche's existing range of MRD diagnostic tools – including the AXELIOS sequencing and Digital LightCycler PCR platforms. Marrying these platforms will further complement Foundation's range of WGS and circulating tumour DNA (ctDNA) monitoring tests. Roche's Saga buyout c
Show less
Read more
Impact Snapshot
Event Time:
GH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GH alerts
High impacting Guardant Health, Inc. news events
Weekly update
A roundup of the hottest topics
GH
News
- Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026Business Wire
- Guardant Health (GH) had its "overweight" rating reaffirmed by Barclays PLC.MarketBeat
- Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know [Yahoo! Finance]Yahoo! Finance
- Guardant Health: Leveraging Liquid Biopsy Testing Momentum [Seeking Alpha]Seeking Alpha
- Guardant Health (GH) Valuation Check After Strong 1 Year Return And Recent 90 Day Pullback [Yahoo! Finance]Yahoo! Finance
GH
Earnings
- 2/19/26 - Beat
GH
Sec Filings
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- 4/16/26 - Form 144
- GH's page on the SEC website